BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Stoke Therapeutics

Stoke Therapeutics logo

Founded
2014
Patents
12
Clinical Trials
2

Technologies

Antisense Oligonucleotides

Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.

Posts Mentioning This Company

Antisense Oligonucleotides Make Sense

  
Antisense oligonucleotides (ASOs) are short (about 12 to 25 nucleotides long), synthetic single strands of DNA or RNA that are complementary to a chosen sequence. They can alter RNA and reduce, restore, or modify protein expression. ASOs interact with proteins on the surface of cells and enter the cytoplasm. Then …
SHARE